靶向生物制剂在银屑病治疗中的应用现状与挑战

Application status and challenges of targeted biological agents in the treatment of psoriasis

美国FDA已批准用于银屑病治疗的靶向生物制剂有6种,包括:阿法西普、依法利珠单抗、英夫利昔单抗、阿达木单抗、依那西普、乌斯奴单抗。本文概述了该6种生物制剂的结构、作用机制、在银屑病治疗中的临床疗效及应用现状。阐述了靶向治疗在发挥良好疗效的同时由于干扰了免疫稳态,可能引起的不良反应与治疗风险及其风险管理。靶向生物制剂为银屑病治疗提供了新途径,同时也面临挑战,长期疗效及安全性尚需更充分的临床验证。

There are 6 types of targeted biological agents that have been approved for the treatment of psoriasis by the United States Food and Drug Administration（ FDA） including Alefacept,Efalizumab,Infliximab,Adalimumab,Etanercept and Ustekinumab.This paper outlines their structure,mechanism of action,clinical efficacy and application status in the treatment of psoriasis. The paper further describes that the targeted biological therapy may also bring a series of adverse reactions and risks by interfering with immune homeostasis when they play a good effect in the treatment of the disease. We also described how to manage these risks. Targeted biological agents provide a new approach for the treatment of psoriasis,but make us face a challenge. Their long-term efficacy and safety still needs to be fully verified in clinic.